Stocks · Healthcare · Drug Manufacturers - General
Gilead Sciences, Inc. GILD
$144.74 -1.87% Close, Oct 2, 2026 · NASDAQ · Market cap $179.47B
Low risk
Next earnings report: Oct 29, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Diluted EPS over the last four quarters was $-2.67, down 153.2% year over year.
- Operating margin narrowed to -4.9% from 27.9% a year earlier.
- Earnings beat analyst estimates in each of the last 10 quarters (average surprise over the last four: +8.0%).
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 41%
- EPS growth (TTM, YoY)Bottom 14%
- FCF growth (TTM, YoY)Top 32%
- Revenue growth, 3-year CAGRBottom 31%
- Revenue growth accelerationTop 28%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 36%
- Gross marginTop 31%
- Operating marginTop 48%
- Accruals (lower is better)Top 6%
- Net debt / EBITDA (lower is better)Bottom 1%
- Interest coverTop 49%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 35%
- Free-cash-flow yieldTop 12%
- EBITDA / enterprise valueTop 37%
- Sales / enterprise valueBottom 40%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 41%
- 6-month returnBottom 46%
- 1-year return vs S&P 500Top 36%
- Distance from 52-week highTop 11%
- Trend checklist (0–4)Top 20%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 42%
- Consecutive EPS beatsTop 6%
- Share of analysts rating BuyBottom 32%
- Upside to consensus price targetBottom 13%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 5%
- Maximum drawdown, 3 yearsTop 4%
- Beta vs S&P 500 (lower is better)Top 9%
- Net debt / EBITDA (lower is better)Bottom 1%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 3.5% | 5.5% | ↑ |
| EPS growth (YoY) | 54.5% | -153.2% | ↓ |
| Gross margin | 78.5% | 79.6% | ↑ |
| Operating margin | 27.9% | -4.9% | ↓ |
| FCF margin | 32.5% | 43.3% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 5.5% | 3.5% | ↑ | Bottom 41% |
| EPS growth (TTM, YoY) | -153.2% | 54.5% | ↓ | Bottom 14% |
| Gross margin | 79.6% | 78.5% | ↑ | Top 31% |
| Operating margin | -4.9% | 27.9% | ↓ | Top 48% |
| Net margin | -10.6% | 21.9% | ↓ | — |
| Free-cash-flow margin | 43.3% | 32.5% | ↑ | — |
| Return on invested capital | -3.7% | — | Top 36% | |
| Revenue growth, 3-year CAGR | 2.6% | — | Bottom 31% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -34.0%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 1.5%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +0.2 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- 36.27×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -1.5×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 2.27%
- Net buyback yield (TTM)
- 0.63%
- Shareholder yield
- 2.90%
- Share count change, 1 year
- -1.0%
- Share count change, 3-year CAGR
- -0.4%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 6, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 10
- Beats in the last 8 reports
- 8 of 8
- Average EPS surprise, last 4
- +8.0%
- Average 2-day reaction, last 8
- +0.1%
- Positive 20 days after report
- 6 of 8
Analysts
- Consensus price target
- $150.00
- Target vs current price
- +3.6%
- Analysts with a rating
- 58
- Share rating Buy or Strong Buy
- 66%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 4, 2026 | +6.9% | +3.1% | +1.5% | +11.6% | — |
| May 7, 2026 | +6.3% | -1.6% | -2.4% | -5.2% | -3.8% |
| Feb 10, 2026 | +2.8% | -2.9% | +2.4% | -2.1% | -10.1% |
| Oct 30, 2025 | +16.0% | -0.1% | +3.4% | +7.6% | +19.0% |
| Aug 7, 2025 | +2.6% | +0.0% | +8.9% | +2.3% | +7.4% |
| Apr 24, 2025 | +1.7% | -0.2% | +0.2% | +1.3% | +1.8% |
| Feb 11, 2025 | +9.2% | +0.7% | +10.2% | +19.8% | +3.6% |
| Nov 6, 2024 | +32.0% | +1.6% | +4.6% | +1.5% | +8.6% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 4, 2026 | -$6.75 | -$7.25 | +6.9% | $7.80B |
| May 7, 2026 | $2.03 | $1.91 | +6.3% | $6.96B |
| Feb 10, 2026 | $1.86 | $1.81 | +2.8% | $7.92B |
| Oct 30, 2025 | $2.47 | $2.13 | +16.0% | $7.77B |
| Aug 7, 2025 | $2.01 | $1.96 | +2.6% | $7.08B |
| Apr 24, 2025 | $1.81 | $1.78 | +1.7% | $6.67B |
| Feb 11, 2025 | $1.90 | $1.74 | +9.2% | $7.57B |
| Nov 6, 2024 | $2.02 | $1.53 | +32.0% | $7.54B |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / EBITDA | 318.5× | — | — | Top 37% |
| EV / Sales | 6.65× | — | — | Bottom 40% |
| Free-cash-flow yield | 7.35% | — | — | Top 12% |
| Earnings yield | -1.84% | — | — | Top 35% |
P/E over the past five years
Range 11.5× – 308.9× since Jun 30, 2021. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- +30.2%
- Earnings per share growth (TTM)
- -153.2%
- Change in P/E multiple
- -12.3%
Most of the move came from a change in the valuation multiple.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 49
- Days above the 200-day average
- 40
- 50-day average slope (20 days)
- +5.2%
- 200-day average slope (20 days)
- +1.8%
- Distance from 50-day average
- +1.1%
- Distance from 200-day average
- +5.9%
- RSI (14)
- 43.8
- Relative volume
- 0.86×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 25.7%
- Volatility vs own 5-year history
- 63th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.33
- Correlation with S&P 500
- 0.20
- Current drawdown from 1-year high
- -7.1%
- Maximum drawdown, 3 years
- -27.7%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Dec 8, 2022 | Jun 18, 2024 | -29.4% | 382 days | 95 days (Nov 1, 2024) |
| Feb 11, 2026 | Jun 10, 2026 | -22.0% | 82 days | Not yet recovered |
| Dec 29, 2021 | Jun 16, 2022 | -21.6% | 117 days | 93 days (Oct 28, 2022) |
| Mar 7, 2025 | May 9, 2025 | -17.5% | 44 days | 62 days (Aug 8, 2025) |
| Oct 12, 2020 | Dec 30, 2020 | -12.2% | 55 days | 12 days (Jan 19, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $179.47B
- EPS, diluted (TTM)
- -$2.67
- Revenue (TTM)
- $30.46B
- Dividend yield
- 2.25%
- 52-week range
- $108.46 – $157.29
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $27.30B | $27.28B | $27.12B | $28.75B | $29.44B |
| Gross profit | $20.70B | $21.62B | $20.62B | $22.50B | $23.21B |
| Operating income | $9.92B | $7.33B | $7.61B | $1.66B | $11.70B |
| Net income | $6.22B | $4.59B | $5.67B | $480.0M | $8.51B |
| EPS (diluted) | $4.93 | $3.64 | $4.50 | $0.38 | $6.78 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.54B | $7.57B | $6.67B | $7.08B | $7.77B | $7.92B | $6.96B | $7.80B |
| Net income | $1.25B | $1.78B | $1.31B | $1.96B | $3.05B | $2.18B | $2.02B | -$10.50B |
| EPS (diluted) | $1.00 | $1.42 | $1.04 | $1.56 | $2.43 | $1.74 | $1.61 | -$8.45 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $11.38B | $9.07B | $8.01B | $10.83B | $10.02B |
| Capital expenditure | -$579.0M | -$728.0M | -$585.0M | -$523.0M | -$563.0M |
| Free cash flow | $10.80B | $8.34B | $7.42B | $10.30B | $9.46B |
| Dividends paid | -$3.60B | -$3.71B | -$3.81B | -$3.92B | -$4.00B |
| Net share buybacks | -$377.0M | -$1.09B | -$768.0M | -$728.0M | -$1.51B |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $3.18B
- Total assets
- $49.36B
- Total liabilities
- $37.62B
- Total debt
- $26.25B
- Net debt
- $23.07B
- Shareholders’ equity
- $11.83B
As of Jun 30, 2026 (filed Aug 6, 2026).
Dividends
| Ex-date | Amount | Paid |
|---|---|---|
| Sep 15, 2026 | $0.82 | Sep 29, 2026 |
| Jun 15, 2026 | $0.82 | Jun 29, 2026 |
| Mar 13, 2026 | $0.82 | Mar 30, 2026 |
| Dec 15, 2025 | $0.79 | Dec 30, 2025 |
| Sep 15, 2025 | $0.79 | Sep 29, 2025 |
| Jun 13, 2025 | $0.79 | Jun 27, 2025 |
| Mar 14, 2025 | $0.79 | Mar 28, 2025 |
| Dec 13, 2024 | $0.77 | Dec 30, 2024 |
Short interest
- Shares sold short
- 18,304,875
- Days to cover
- 3.65
- Change vs previous report
- -20.4%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Jan 28, 2013
- 2-for-1
- Jun 25, 2007
- 2-for-1
- Sep 7, 2004
- 2-for-1
- Mar 8, 2002
- 2-for-1
- Feb 22, 2001
- 2-for-1